Ultragenyx Pharmaceutical (RARE)
(Real Time Quote from BATS)
$58.95 USD
+1.25 (2.17%)
Updated Sep 19, 2024 12:37 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Ultragenyx Pharmaceutical Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -606.64 | -707.42 | -454.03 | -186.57 | -402.73 |
Depreciation/Amortization & Depletion | 13.16 | 20.92 | 19.85 | 13.11 | 2.32 |
Net Change from Assets/Liabilities | -13.48 | 61.87 | -63.24 | 104.66 | -18.08 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 132.15 | 244.16 | 158.72 | -63.43 | 73.10 |
Net Cash From Operating Activities | -474.81 | -380.47 | -338.70 | -132.22 | -345.38 |
Property & Equipment | -44.27 | -116.12 | -73.09 | -43.91 | -24.83 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -75.03 | 0.00 | 0.00 | 0.00 |
Investments | 219.82 | -69.66 | -121.34 | -129.66 | 11.79 |
Other Investing Activities | -7.55 | -30.84 | -0.94 | -5.56 | 0.00 |
Net Cash from Investing Activities | 168.00 | -291.65 | -195.37 | -179.12 | -13.04 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 388.17 | 10.81 | 119.04 | 600.51 | 365.07 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.03 | 490.40 | -0.49 | -0.24 | 314.23 |
Net Cash from Financing Activities | 388.14 | 501.21 | 118.55 | 600.27 | 679.31 |
Effect of Exchange Rate Changes | 0.46 | -1.08 | -1.19 | 1.12 | -0.17 |
Net Change In Cash & Equivalents | 81.80 | -171.98 | -416.71 | 290.05 | 320.72 |
Cash at Beginning of Period | 137.60 | 309.59 | 726.29 | 436.24 | 115.53 |
Cash at End of Period | 219.40 | 137.60 | 309.59 | 726.29 | 436.24 |
Diluted Net EPS | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 |
Fiscal Year End for Ultragenyx Pharmaceutical Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -302.28 | -170.68 | -606.64 | -483.45 | -323.80 |
Depreciation/Amortization & Depletion | 11.00 | 5.09 | 13.16 | 8.89 | 4.38 |
Net Change from Assets/Liabilities | -39.66 | -56.02 | -13.48 | -28.41 | -31.21 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 63.25 | 30.89 | 132.15 | 112.06 | 77.59 |
Net Cash From Operating Activities | -267.69 | -190.73 | -474.81 | -390.90 | -273.03 |
Property & Equipment | -5.22 | -3.21 | -44.27 | -42.67 | -38.97 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 174.83 | 109.71 | 219.82 | 324.96 | 256.54 |
Other Investing Activities | -14.61 | -12.07 | -7.55 | -7.28 | -6.85 |
Net Cash from Investing Activities | 155.00 | 94.44 | 168.00 | 275.02 | 210.72 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 384.88 | -0.06 | 388.17 | 57.56 | 32.33 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.03 | -0.03 | -0.03 |
Net Cash from Financing Activities | 384.88 | -0.06 | 388.14 | 57.53 | 32.30 |
Effect of Exchange Rate Changes | -1.33 | -0.68 | 0.46 | -0.64 | 0.08 |
Net Change In Cash & Equivalents | 270.86 | -97.03 | 81.80 | -58.99 | -29.93 |
Cash at Beginning of Period | 219.40 | 219.40 | 137.60 | 137.60 | 137.60 |
Cash at End of Period | 490.26 | 122.37 | 219.40 | 78.61 | 107.67 |
Diluted Net EPS | -1.52 | -2.03 | -1.44 | -2.23 | -2.25 |